β-Lactam pharmacokinetics during extracorporeal membrane oxygenation therapy: A case-control study.

Most adult patients receiving extracorporeal membrane oxygenation (ECMO) require antibiotic therapy, however the pharmacokinetics of β-lactams have not been well studied in these conditions. In this study, data from all patients receiving ECMO support and meropenem (MEM) or piperacillin/tazobactam (TZP) were reviewed. Drug concentrations were measured 2h after the start of a 30-min infusion and just before the subsequent dose. Therapeutic drug monitoring (TDM) results in ECMO patients were matched with those in non-ECMO patients for (i) drug regimen, (ii) renal function, (iii) total body weight, (iv) severity of organ dysfunction and (v) age. Drug concentrations were considered adequate if they remained 4-8× the clinical MIC breakpoint for Pseudomonas aeruginosa for 50% (TZP) or 40% (MEM) of the dosing interval. A total of 41 TDM results (27 MEM; 14 TZP) were obtained in 26 ECMO patients, with 41 matched controls. There were no significant differences in serum concentrations or pharmacokinetic parameters between ECMO and non-ECMO patients, including Vd [0.38 (0.27-0.68) vs. 0.46 (0.33-0.79)L/kg; P=0.37], half-life [2.6 (1.8-4.4) vs. 2.9 (1.7-3.7)h; P=0.96] and clearance [132 (66-200) vs. 141 (93-197)mL/min; P=0.52]. The proportion of insufficient (13/41 vs. 12/41), adequate (15/41 vs. 19/41) and excessive (13/41 vs. 10/41) drug concentrations was similar in ECMO and non-ECMO patients. Achievement of target concentrations of these β-lactams was poor in ECMO and non-ECMO patients. The influence of ECMO on MEM and TZP pharmacokinetics does not appear to be significant.

[1]  J. Fraser,et al.  Altered antibiotic pharmacokinetics during extracorporeal membrane oxygenation: cause for concern? , 2013, The Journal of antimicrobial chemotherapy.

[2]  J. Rello,et al.  DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  H. Mulla,et al.  In vitro evaluation of sedative drug losses during extracorporeal membrane oxygenation , 2000, Perfusion.

[4]  J. Fraser,et al.  ECMO – the clinician’s view , 2012 .

[5]  Kiran Shekar,et al.  Sequestration of drugs in the circuit may lead to therapeutic failure during extracorporeal membrane oxygenation , 2012, Critical Care.

[6]  D. Tibboel,et al.  Microanalysis of β-Lactam Antibiotics and Vancomycin in Plasma for Pharmacokinetic Studies in Neonates , 2008, Antimicrobial Agents and Chemotherapy.

[7]  G. Annich,et al.  Sedative clearance during extracorporeal membrane oxygenation , 2005, Perfusion.

[8]  J. Vincent,et al.  Case-Control Study of Drug Monitoring of β-Lactams in Obese Critically Ill Patients , 2012, Antimicrobial Agents and Chemotherapy.

[9]  J. Vincent,et al.  Continuous infusion of vancomycin in septic patients receiving continuous renal replacement therapy. , 2013, International journal of antimicrobial agents.

[10]  Diana Elbourne,et al.  Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial , 2009, The Lancet.

[11]  R. Thiagarajan,et al.  Extracorporeal Life Support Organization Registry Report 2012 , 2013, ASAIO journal.

[12]  W. Knaus,et al.  APACHE II: a severity of disease classification system. , 1985 .

[13]  Frédérique Jacobs,et al.  Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock , 2010, Critical care.

[14]  O. Cars,et al.  Selection of Resistant Streptococcus pneumoniae during Penicillin Treatment In Vitro and in Three Animal Models , 2003, Antimicrobial Agents and Chemotherapy.

[15]  J. Vincent,et al.  The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure , 1996, Intensive Care Medicine.

[16]  J. Vincent,et al.  Rapid quantification of six β-lactams to optimize dosage regimens in severely septic patients. , 2013, Talanta.

[17]  R. Schumacher,et al.  Gentamicin Pharmacokinetics in Term Neonates Receiving Extracorporeal Membrane Oxygenation , 1992, Pharmacotherapy.

[18]  Michael Bailey,et al.  Extracorporeal Membrane Oxygenation for 2009 Influenza A(H1N1) Acute Respiratory Distress Syndrome. , 2009, JAMA.

[19]  J. Turnidge,et al.  Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. , 1988, The Journal of infectious diseases.

[20]  J. Vincent,et al.  Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy , 2011, Critical care.

[21]  J. Vincent,et al.  Can changes in renal function predict variations in β-lactam concentrations in septic patients? , 2013, International journal of antimicrobial agents.

[22]  Jane Alcorn,et al.  Pharmacokinetics in the newborn. , 2003, Advanced drug delivery reviews.

[23]  D. Rosen,et al.  In vitro variability in fentanyl absorption by different membrane oxygenators. , 1990, Journal of cardiothoracic anesthesia.

[24]  D. Tibboel,et al.  Determinants of drug absorption in different ECMO circuits , 2010, Intensive Care Medicine.

[25]  J. Vincent,et al.  Can population pharmacokinetic modelling guide vancomycin dosing during continuous renal replacement therapy in critically ill patients? , 2013, International journal of antimicrobial agents.

[26]  M. Buck.  Pharmacokinetic Changes During Extracorporeal Membrane Oxygenation , 2003, Clinical pharmacokinetics.

[27]  S. Scolletta,et al.  Appropriate Antibiotic Dosage Levels in the Treatment of Severe Sepsis and Septic Shock , 2011, Current infectious disease reports.

[28]  Elazer R. Edelman,et al.  Adv. Drug Delivery Rev. , 1997 .

[29]  J. Fraser,et al.  Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation. , 2012, Journal of critical care.